在Hirschsprung疾病中持续污染的治疗与先进的节制阴囊
Thomas Xu1, Rachel Hanke1, Inbal Samuk1
1Division of Colorectal and Pelvic Reconstruction, Children's National Hospital, Washington, District of Columbia.
The Journal of surgical research
|August 17, 2024
概括
预先升级的禁欲透水 (ACE) 有效地管理了手术后在希尔施普朗格病 (HD) 患者的污染. 大多数患者在4个月内实现清洁,尽管超运动性会影响长期结果.
科学领域:
- 儿科手术 儿科手术
- 胃肠病学 胃肠病学
- 结肠直肠手术 结肠直肠手术
背景情况:
- 赫施普朗格病 (HD) 经常导致纠正手术后持续的污垢.
- 标准的治疗方法,如药和直肠清洁剂,可能无法解决污垢.
- 升级前失禁透镜 (ACE) 提出了耐火污染的替代管理策略.
研究的目的:
- 评估在患有赫斯普朗氏病 (HD) 的儿科患者手术后出现污染的前期禁欲透水 (ACE) 的疗效.
- 用ACE来确定患者达到便节所需的时间.
- 确定影响ACE在污染管理中的成功因素.
主要方法:
- 从2020年1月到2023年1月接受ACE治疗的30名患有持续污染的HD患者的回顾性评估.
- 主要结局:达到便节的时间,定义为每天的排便,最小的事故,和明确的X射线便负担.
- 卡普兰-梅尔分析和考克斯比例危险回归被用来评估节的时间和相关因素.
主要成果:
- 创建ACE时的平均年龄为6.5岁,平均随访时间为11.5个月.
- 65%的患者在4个月内实现了节制,76%在1年内实现了节制.
- 患有肠道多动性的患者在1年内表现出明显更高的持续污染率 (80%对13%,P=0.01).
结论:
- 升级前的禁欲透水 (ACE) 是一种有效的治疗,用于污染的患者与希尔施普朗格病.
- 大多数接受ACE治疗的患者在4个月内实现了便失禁.
- 肠道多动性是持续污染的重要危险因素,尽管ACE治疗.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146
Inflammatory Bowel Disease V: Surgical Management
134
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
134
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Irritable Bowel Syndrome III: Medical and Nursing Management
188
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
188
Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
66
Sigmoidoscopy and laparoscopy are distinct medical procedures that enable physicians to internally inspect different parts of the GI tract. Although they serve different purposes, each is essential for diagnosing and, in some cases, treating various medical conditions.
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
66
Drugs for Treatment of Ulcerative Colitis in IBD
131
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
131


